VPIX Medical's Digital Biopsy Platform 'cCeLL' Recognized as a Next-Generation World-Class Product

On the 30th, VPIX Medical announced that its digital biopsy platform, cCeLL, has been recognized as a Next-Generation World-Class Product by the Ministry of Trade, Industry, and Energy (MOTIE) and KOTRA.

The Next-Generation World-Class Product certification is awarded annually to products evaluated for their market potential and growth prospects, 

with the expectation that they can achieve "World-Class Product" status within the next seven years. This initiative aims to diversify Korea's exports and secure future growth engines.

cCeLL is a real-time digital biopsy platform that provides cell-level tissue imaging during surgery in a non-invasive manner, allowing surgeons to accurately identify cancerous tissues while minimizing damage to normal tissues.

The platform is available in two product types: Ex vivo (outside the body) and In vivo (inside the body) diagnostic devices. The cCeLL-Ex vivo device offers diagnostic speeds that are over 50% faster than conventional frozen section biopsies, with diagnostic accuracy exceeding 90%. These findings were published in the international journal Scientific Reports, and the device has undergone successful validation through an international multi-center clinical study involving institutions such as Korea University Anam Hospital, Seoul National University Hospital, Samsung Medical Center, and St. Michael's Hospital. Meanwhile, the cCeLL-In vivo device received FDA 510(k) clearance in August of this year, paving the way for global market entry.

As a resident company of Seoul Bio Hub, VPIX Medical is expanding the technology's application to various indications, including gastric cancer, pancreatic cancer, and prostate cancer, 

while also integrating AI-based diagnostic algorithms to enhance cancer diagnostic solutions.

VPIX Medical stated that this certification will accelerate its efforts toward technological advancement and global market penetration. 

Hwang Kyung-min, CEO of VPIX Medical, expressed: "We are honored that cCeLL has been recognized as a Next-Generation World-Class Product. Moving forward, we will strive to achieve the World-Class Product certification by further expanding into overseas markets."

Reporter: Seong-Jun Park | Email:mediapark@ekn.kr
Source: Energy Economic News, November 30, 2024

• Herald, The Asia Economy, English Yakup Daily
• Rapportian, Enetnes, Venturesquare
• Energy Economic News, ITbiznews, nbntv